Viking Therapeutics Inc (VKTX) Short Interest Up 12.2% in October

Viking Therapeutics Inc (NASDAQ:VKTX) was the recipient of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 22,218,913 shares, an increase of 12.2% from the October 15th total of 19,809,519 shares. Currently, 40.3% of the shares of the company are sold short. Based on an average daily volume of 2,924,213 shares, the days-to-cover ratio is presently 7.6 days.

In related news, major shareholder Ligand Pharmaceuticals Inc sold 262,881 shares of the company’s stock in a transaction on Tuesday, September 25th. The shares were sold at an average price of $19.15, for a total transaction of $5,034,171.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.90% of the stock is owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the business. FMR LLC bought a new stake in Viking Therapeutics in the 3rd quarter valued at $125,858,000. American International Group Inc. increased its holdings in Viking Therapeutics by 21.3% in the 3rd quarter. American International Group Inc. now owns 34,403 shares of the biotechnology company’s stock valued at $599,000 after buying an additional 6,036 shares during the period. BlackRock Inc. increased its holdings in Viking Therapeutics by 14.0% in the 3rd quarter. BlackRock Inc. now owns 3,349,901 shares of the biotechnology company’s stock valued at $58,355,000 after buying an additional 411,256 shares during the period. Bank of New York Mellon Corp increased its holdings in Viking Therapeutics by 11.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 385,484 shares of the biotechnology company’s stock valued at $6,714,000 after buying an additional 39,455 shares during the period. Finally, Eagle Asset Management Inc. increased its holdings in Viking Therapeutics by 68.1% in the 3rd quarter. Eagle Asset Management Inc. now owns 130,987 shares of the biotechnology company’s stock valued at $2,281,000 after buying an additional 53,076 shares during the period. 53.56% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Viking Therapeutics stock opened at $12.33 on Friday. The firm has a market capitalization of $833.44 million, a price-to-earnings ratio of -15.61 and a beta of 2.92. Viking Therapeutics has a 52-week low of $2.24 and a 52-week high of $24.00.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.01. On average, equities research analysts forecast that Viking Therapeutics will post -0.44 earnings per share for the current fiscal year.

Several equities analysts recently commented on VKTX shares. SunTrust Banks started coverage on shares of Viking Therapeutics in a research note on Friday, July 20th. They set a “buy” rating and a $14.00 target price for the company. BidaskClub upgraded shares of Viking Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, July 21st. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Viking Therapeutics in a research note on Friday, August 10th. William Blair reiterated an “outperform” rating on shares of Viking Therapeutics in a research note on Friday, August 10th. Finally, Raymond James reiterated an “outperform” rating and set a $43.00 target price (up from $15.00) on shares of Viking Therapeutics in a research note on Tuesday, September 18th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $28.17.

COPYRIGHT VIOLATION WARNING: “Viking Therapeutics Inc (VKTX) Short Interest Up 12.2% in October” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/11/10/viking-therapeutics-inc-vktx-short-interest-up-12-2-in-october.html.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

Read More: Understanding the different types of bonds

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply